MD Newsline

In this episode of MD Newsline, Dr. Pooja Singh, an internal medicine physician with expertise in hospital medicine, community medicine, and startup medicine, explores how leveraging technology, wearable technology, and continuous patient health data can transform primary care. Dr. Singh shares insights from her foundational work at Forward Health, emphasizing how extended consultation times, smart screens, and unobtrusive scribes allow physicians to deliver holistic, preventive care rather than brief, reactive visits. The discussion covers the current landscape of patient data interaction, addressing how tools like whole-body MRIs from Prenuvo and Function Health remove barriers to health information. She also examines the clinical integration of artificial intelligence (AI) in electronic medical record (EMR) systems like Ultralight, highlighting its role in eliminating "pajama time," providing clear after-visit summaries, and creating alarms for acute events like atrial fibrillation (AFib) on Apple Watches. Finally, Dr. Singh discusses self-advocacy through health tracking apps like Clue, Flo, Yuka, and Apple Health, and outlines a vision for preventing chronic conditions like cardiovascular disease, cancer, and obesity through continuous, long-term health partnerships.   Episode Highlights   The Startup Journey and Redefining Primary Care Dr. Pooja Singh reflects on her clinical journey spanning hospital medicine, community medicine, and startup medicine at Forward Health. Founded by Adrian Aoun, Robert Sebastian, and Ilya Abroff, Forward Health sought to make healthcare accessible through technology-driven, patient-centered care. Operating in locations across San Francisco, Los Angeles, and New York, the platform utilized 30- to 60-minute patient visits, unobtrusive remote scribes, and interactive smart screens. Dr. Singh emphasizes that patients are defined by continuous, multi-dimensional data points across their lifespan rather than isolated, single abnormal lab results or blood pressure readings.   Wearables, Preventive Health, and Patient Agency The conversation addresses the rise of wearable technology, including Apple Watches, Whoop, Oura rings, and Fitbits, as well as direct-access testing platforms like Prenuvo and Function Health. Dr. Singh contrasts traditional, reactive healthcare with a preventive model where clinicians interpret continuous health data, lifestyle factors, and genetics to lower long-term disease risk. In this modern framework, the patient acts as the primary agent of their own health, supported by extended conversations with their care team.   Leveraging AI and Modern EMR Systems Addressing physician burnout and administrative strain, Dr. Singh discusses the role of artificial intelligence (AI) in next-generation electronic medical record (EMR) systems like Ultralight. Rather than replacing human judgment, human-in-the-loop AI automates clinical documentation, generates structured after-visit summaries, and eliminates "pajama time" for physicians. Modern EMRs can also integrate real-time wearable data to trigger automated safety alerts for conditions such as atrial fibrillation (AFib), notifying health systems to arrange rapid evaluations (e.g., an electrocardiogram (EKG)) before severe outcomes like a stroke occur.   Navigating Fragmented Health Records and Self-Advocacy Dr. Singh outlines practical strategies for aggregating fragmented health records across disparate clinical systems (such as Epic platform interoperability, MyChart, Apple Health, and historical platforms like Torch, which was acquired by OpenEvidence AI). She encourages patients to actively track their health metrics and seek collaborative care partners who act as health coaches rather than dismissive gatekeepers.   Family Health History, Genetics, and Lifestyle Education The episode explores how patients can collect, maintain, and pass down health data, genetics, and family medical histories to future generations. Dr. Singh discusses how tracking perimenopausal and menopausal symptoms across 35 distinct clinical presentations (such as memory loss and brain fog) using apps like Clue and Flo empowers women to advocate for their health. She also shares practical examples of empowering younger generations, such as using nutritional scanning apps like Yuka to identify high-risk preservatives in foods and make informed choices.   Key Takeaway Transforming primary care requires moving away from brief, 15-minute reactive appointments to a continuous, technology-enabled healthcare model. By integrating artificial intelligence, wearable technology, genetics, and modern EMR systems, clinicians can partner with patients to interpret multi-layered health data, streamline documentation, prevent chronic conditions like cardiovascular disease and cancer, and place individuals in control of their own health journey.   RESOURCES Website — https://mdnewsline.com/ Newsletter — https://mdnewsline.com/subscribe/ Dr. Pooja Singh — https://www.linkedin.com/in/poojasinghmd/ Forward Health — https://goforward.com/

In this episode of MD Newsline, Dr. Iqra Aftab, a practicing rheumatologist specializing in complex autoimmune diseases, provides a comprehensive overview of the modern spondyloarthritis (SpA) spectrum. Dr. Aftab clarifies the umbrella concept of spondyloarthritis, detailing its subtypes—including psoriatic arthritis, IBD-associated arthritis, reactive arthritis, and ankylosing spondylitis—while dissecting the critical distinction between radiographic axial spa and non-radiographic axial spa. She addresses the rising incidence of mechanical back pain, highlighting key clinical red flags for inflammatory back pain in patients under age 45. The discussion explores practical application of the ACR 2026 guidelines, ASAS/SPARTAN criteria, and the EULAR 2026 imaging update, emphasizing the sequence of plane radiographs, MRI of the sacroiliac joints, and low-dose CT. Furthermore, Dr. Aftab outlines step-up treatment algorithms from NSAIDs to TNF inhibitors, IL-17 inhibitors, and JAK inhibitors, while emphasizing extra-articular manifestations (anterior uveitis, psoriasis, inflammatory bowel disease), patient self-advocacy, multidisciplinary care, and lifestyle interventions like exercise, physiotherapy, and smoking cessation.   Episode Highlights   Demystifying the Spondyloarthritis Spectrum Dr. Aftab breaks down spondyloarthritis as a family of inflammatory arthritides affecting the spine, tendons, and ligamentous insertions (entheses). She explains that the overarching umbrella encompasses psoriatic arthritis, reactive arthritis, IBD-associated arthritis, and axial spondyloarthritis. Within axial disease, she clarifies that ankylosing spondylitis is now formally categorized as radiographic axial spa, whereas disease lacking structural joint damage on plain films is classified as non-radiographic axial spa.   Differentiating Inflammatory from Mechanical Back Pain While mechanical back pain improves with rest and worsens with activity, inflammatory back pain presents with severe morning stiffness (patients often describe feeling like a "tin man" or "tin woman") and improves significantly with exercise and anti-inflammatory medications. Dr. Aftab stresses that persistent symptoms in patients under age 45 should immediately raise clinical suspicion for axial spondyloarthritis regardless of initial radiographic findings.   Navigating Diagnostic Delay and Extra-Articular Manifestations Diagnostic delays in axial spondyloarthritis frequently stretch from symptom onset to diagnosis, often taking up to five years. Clinicians must recognize extra-articular manifestations—including anterior uveitis in the eyes, psoriasis on the skin, and inflammatory bowel disease (ulcerative colitis or Crohn's disease) in the gut—rather than evaluating these systemic features in isolation.   Imaging Modalities and Guideline Updates According to ACR 2026 guidelines and the EULAR 2026 imaging update, plane radiographs remain first-line imaging. When ordering x-rays, clinicians should request an anterior-posterior (AP) pelvis view specifically focusing on the sacroiliac joints rather than a standard lumbar spine view alone. If radiographs are normal, clinicians must order an MRI of the sacroiliac joints. Low-dose CT is primarily reserved for cases where MRI is unavailable or contraindicated. Dr. Aftab emphasizes that ASAS/SPARTAN classification criteria are designed for clinical trials and research populations, whereas individual clinical diagnosis requires holistic assessment.   Therapeutic Algorithms: NSAIDs, Biologics, and Targeted Synthetics Initial therapy requires a full trial of NSAIDs, defined as two different anti-inflammatories at maximal dose for two to four weeks each (a total trial of four to eight weeks). If active disease persists, clinicians escalate treatment per ACR guidelines to TNF inhibitors or IL-17 inhibitors, both of which carry equal recommendation strength. JAK inhibitors are positioned later in the algorithm due to potential risks, including cardiovascular events, thromboembolic events, and malignancies.   Comorbidity-Guided Treatment Selection and Tapering Co-existing conditions directly govern biologic choice: patients with recurrent uveitis or inflammatory bowel disease should receive monoclonal antibody TNF inhibitors (such as adalimumab or infliximab), whereas soluble receptors like etanercept are not indicated. While IL-17 inhibitors effectively target psoriasis, they must be used with caution as they can exacerbate underlying inflammatory bowel disease. When switching mechanisms, guidelines recommend moving to a different drug class after primary failure. For sustained remission, therapy should be gradually tapered by expanding dosing intervals rather than abrupt discontinuation to prevent rebound flares.   Addressing Systemic Fatigue, Lifestyle, and Patient Advocacy Systemic fatigue in spondyloarthritis can stem directly from active autoimmune disease activity or secondary factors such as anemia, poor sleep architecture, and psychological distress. Non-pharmacologic management rests on exercise and physiotherapy as core therapeutic modalities, alongside aggressive smoking cessation, as active smoking correlates with heightened disease activity. Dr. Aftab encourages primary care clinicians to issue early referrals to rheumatology and urges patients to maintain strong self-advocacy throughout their diagnostic journey.   Key Takeaway Normal plain radiographs do not rule out axial spondyloarthritis. Primary care clinicians should maintain a high index of suspicion for inflammatory back pain in young patients, ordering targeted sacroiliac joint MRI imaging and making early referrals to rheumatology to prevent years of unnecessary diagnostic delay, structural damage, and functional impairment.   RESOURCES Website — https://mdnewsline.com/ Newsletter — https://mdnewsline.com/subscribe/ Dr Iqra Aftab — https://www.linkedin.com/in/iqra-a-206b2630/

In this episode of MD Newsline, Dr. Iqra Aftab, a double board-certified rheumatologist and internal medicine physician, offers a practical guide to recognizing, diagnosing, and managing axial spondyloarthritis (axial SpA), with a particular focus on non-radiographic disease. She explains why axial SpA can be overlooked in younger patients with persistent back pain and how clinicians can recognize inflammatory patterns even when conventional imaging appears normal. Dr. Aftab walks through the spondyloarthritis spectrum, distinguishing radiographic axial SpA from non-radiographic axial SpA and emphasizing that the absence of joint damage on X-rays does not mean the disease is mild or insignificant. She highlights clinical clues such as morning stiffness, improvement with exercise and anti-inflammatories, and younger age, while also discussing extra-articular manifestations including uveitis, psoriasis, and inflammatory bowel disease. The conversation also explores the appropriate role of X-rays and MRI, the distinction between classification and diagnostic criteria, treatment escalation from NSAIDs to biologic and targeted therapies, and how extra-articular disease can influence treatment selection. Dr. Aftab addresses fatigue, functional impairment, lifestyle management, multidisciplinary care, and the importance of early rheumatology referral to reduce diagnostic delays. Episode Highlights: Recognizing Inflammatory Back Pain: Dr. Aftab explains the key features that can distinguish inflammatory from mechanical back pain, including morning stiffness, improvement with exercise and anti-inflammatories, and younger age. Understanding Non-Radiographic Axial SpA: A normal X-ray does not rule out axial SpA. Dr. Aftab emphasizes that non-radiographic disease can still cause significant pain, disability, and reduced quality of life. Recognizing Extra-Articular Manifestations: Uveitis, psoriasis, and inflammatory bowel disease can provide important clues to an underlying spondyloarthritis diagnosis. Choosing Imaging and Treatment: The discussion covers when to move from X-rays to MRI and when to escalate from NSAIDs to biologic or targeted therapies. Matching Therapy to the Patient: Dr. Aftab explains how extra-articular disease, treatment risks, patient preferences, and practical considerations can influence biologic selection and treatment changes. Addressing Fatigue and Daily Function: Fatigue may stem from active inflammation or other factors, while assessing work, family life, and daily activities can reveal the true impact of disease. Knowing When to Refer: Persistent back pain with inflammatory features in a younger patient should prompt rheumatology referral, even when X-rays are normal or the diagnostic workup is incomplete. Key Takeaway: Dr. Aftab emphasizes that a normal X-ray does not rule out non-radiographic axial SpA. Recognizing inflammatory back pain, considering appropriate imaging, connecting extra-articular symptoms, and referring patients early can help reduce diagnostic delays and support timely treatment. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/

In this episode of MD Newsline, Dr. Hina Tareen, a double board-certified rheumatologist and internal medicine physician, provides a comprehensive and practical guide to diagnosing and managing Sjögren's syndrome in everyday clinical practice. Drawing from her experience in private practice, she highlights the challenges of recognizing this often-overlooked autoimmune condition and emphasizes the importance of early suspicion and multidisciplinary care. Dr. Tareen walks through the hallmark symptoms of Sjögren's, including dry eyes and dry mouth, while underscoring the broader systemic nature of the disease. She discusses how to differentiate clinically significant disease from common dryness complaints, outlines a step-by-step diagnostic framework, and explores management strategies ranging from symptomatic relief to systemic immunosuppressive therapy. The conversation also addresses common pitfalls in diagnosis, the role of collaboration across specialties, and the importance of patient education and long-term monitoring. With emerging research on novel biomarkers and evolving treatment options, this episode offers valuable insights for clinicians navigating the complexities of Sjögren's syndrome. Episode Highlights: Recognizing Early Signs of Sjögren's Syndrome Dr. Tareen explains that persistent dry eyes and dry mouth are the most common presenting symptoms, but clinicians must also look beyond dryness to identify fatigue, joint pain, and systemic features. Distinguishing Sjögren's from Benign Dryness Clinical context is key—frequent use of artificial tears, difficulty swallowing dry foods, and associated systemic symptoms help differentiate Sjögren's from more common causes of dryness. Primary vs Secondary Sjögren's Syndrome Sjögren's often coexists with other autoimmune diseases like rheumatoid arthritis and lupus. Identifying whether the disease is primary or secondary is essential for guiding management. Diagnostic Approach and Laboratory Evaluation A thorough history and physical exam remain foundational. Key labs include ANA, ENA panel, inflammatory markers, complement levels, and organ function tests, with biopsy reserved for unclear cases. Managing Seronegative or Atypical Cases Patients who do not meet full criteria may still be treated based on clinical suspicion. Additional testing, including salivary gland biopsy, may help confirm the diagnosis when necessary. Assessing and Monitoring Systemic Involvement Clinicians must remain vigilant for extra-glandular manifestations, including renal, pulmonary, neurologic, and hematologic involvement, which may require imaging, lab monitoring, and specialist referrals. Stepwise Treatment Strategy Management begins with symptomatic relief for dryness, followed by systemic therapy such as hydroxychloroquine, methotrexate, or mycophenolate based on organ involvement and disease severity. Addressing Fatigue and Quality of Life Fatigue is often multifactorial. Dr. Tareen emphasizes evaluating sleep, mood, nutritional deficiencies, and overall disease control to improve patient outcomes. Long Diagnostic Journeys and Missed Opportunities Many patients experience years of symptoms before diagnosis due to vague presentations. Increasing awareness among clinicians can help reduce delays and improve care. Lymphoma Risk and Long-Term Monitoring While Sjögren's carries an increased lymphoma risk, careful monitoring through labs and clinical evaluation helps identify higher-risk patients and guide timely referrals. Patient Education and Self-Management Hydration, eye and dental care, and lifestyle modifications play a crucial role. Empowering patients with knowledge helps them better manage their condition and advocate for their care. Future Directions in Sjögren's Research Emerging biomarkers and new therapeutic options are on the horizon, offering hope for earlier diagnosis and more targeted treatment strategies. Key Takeaway: Dr. Tareen emphasizes that Sjögren's syndrome is a complex, systemic autoimmune disease that often presents subtly. Early recognition, a thorough clinical approach, and multidisciplinary collaboration are essential to improving patient outcomes and preventing long-term complications.  Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Hina Tareen: Here

In this episode of MD Newsline, Dr. Jill Weintraub, founder of Integrative Rheumatology Consultants, explores the complexities of axial spondyloarthritis, a chronic inflammatory condition that often goes undiagnosed for years. Dr. Weintraub provides a comprehensive overview of this umbrella disease, including its radiographic and non-radiographic forms, and explains why early recognition is critical to preventing long-term damage. She highlights the key differences between inflammatory and mechanical back pain, the challenges in diagnosing women, and the role of advanced imaging such as MRI. The conversation also dives into the interplay between genetics, the gut microbiome, and immune system dysfunction, as well as how modern therapies—from TNF inhibitors to JAK inhibitors—are transforming patient outcomes. Dr. Weintraub emphasizes the importance of integrating lifestyle interventions like exercise and physical therapy alongside medical treatment to improve long-term quality of life. Episode Highlights: Understanding Axial Spondyloarthritis Dr. Jill Weintraub explains axial spondyloarthritis as an umbrella of inflammatory diseases primarily affecting the spine, while also involving joints and entheses. She distinguishes between radiographic (ankylosing spondylitis) and non-radiographic forms, emphasizing how evolving definitions are improving diagnosis. Recognizing Inflammatory Back Pain A key diagnostic feature is inflammatory back pain, typically presenting before age 40 with morning stiffness that improves with movement. Dr. Weintraub contrasts this with mechanical back pain and highlights why this distinction is critical in clinical practice. Diagnostic Challenges and Delays Diagnosis can take years, especially in women, due to atypical presentations and central sensitization of pain. She stresses the importance of patient advocacy and clinician awareness to reduce delays. Role of Imaging and Clinical Evaluation MRI of the pelvis with appropriate sequences is essential for early detection, particularly in non-radiographic disease. However, Dr. Weintraub underscores that diagnosis remains largely clinical, as lab markers may often appear normal. Genetics, Microbiome, and Immune Interplay The episode explores how genetic factors like HLA-B27, combined with environmental triggers and gut microbiome imbalances, contribute to disease development and progression. Treatment Strategies and Biologic Selection Dr. Weintraub discusses how treatment is tailored to the whole patient, comparing TNF inhibitors, IL-17 inhibitors, and JAK inhibitors, while weighing risks such as infection, cardiovascular events, and long-term safety. Importance of Exercise and Integrative Care Exercise, physical therapy, and lifestyle interventions are essential components of treatment. While supplements and diet can support symptom relief, they are not substitutes for disease-modifying therapies. Managing Overlapping Conditions She highlights the importance of coordinating care for patients with related conditions such as psoriasis, uveitis, and inflammatory bowel disease, ensuring treatment choices address multiple disease pathways. Future Directions in Research Emerging research on the gut microbiome offers promising insights into new therapeutic targets, potentially transforming how axial spondyloarthritis is managed in the future. Key Takeaway Early recognition of inflammatory back pain is critical in axial spondyloarthritis. A combination of clinical awareness, appropriate imaging, and personalized treatment—including both pharmacologic and lifestyle approaches—can significantly improve patient outcomes and prevent long-term disease progression. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Jill Weintraub: Here

In this episode of MD Newsline, Dr. Justin Morales, Addiction Psychiatry Fellow at Mass General Brigham Harvard Medical System, explores how our understanding of addiction has evolved from a simple reward-pathway model to a comprehensive biopsychosocial framework. Dr. Morales discusses substance use disorders alongside emerging behavioral addictions such as social media overuse, gaming, and binge behaviors. He explains how dopamine signaling, reward-based learning, and executive function circuits influence compulsivity and craving—and why modern overstimulation may blur the line between habit and addiction. The conversation also examines cannabis potency trends, co-occurring psychiatric conditions, sports psychiatry, and emerging neuromodulation treatments for addiction. Episode Highlights: The Biopsychosocial Model of Addiction Dr. Morales outlines the shift from a narrow neurochemical model to a holistic framework incorporating biology, psychology, and social environment. Treatment may involve medication, therapy, and social interventions working together rather than in isolation. Substance vs. Behavioral Addictions While behavioral addictions like social media overuse are not formally classified the same way as substance use disorders in DSM-5, clinicians can adapt similar criteria—such as functional impairment, compulsivity, and high-risk behaviors—to assess severity. Cannabis Potency and Psychiatric Risk Modern cannabis products are significantly more potent than in prior decades. Dr. Morales highlights growing concerns about high-THC exposure potentially contributing to psychosis and mood destabilization. Co-Occurring Mood Disorders Over half of individuals with substance use disorders have a co-occurring psychiatric condition. Dr. Morales discusses common treatment pitfalls—such as addressing depression without addressing substance use—and emphasizes integrated care. Digital Overstimulation and Dopamine Social media and gaming platforms leverage reward-based learning similar to substances. The brain adapts to chronic overstimulation, which may lead to reduced baseline motivation and mood flattening. Dopamine Detox: Myth or Medicine? Although strong research evidence is limited, reducing overstimulation may help the brain recalibrate toward homeostasis and improve natural reward sensitivity. Integrated Treatment for Multiple Addictions Dr. Morales explains how clinicians may treat different substances pharmacologically while addressing underlying psychological drivers—such as avoidance or emotional numbing—through unified therapy strategies. Sports Psychiatry and Identity Athletes face unique pressures tied to performance, injury, career transitions, and identity fusion. Substance use and mood disorders may emerge during times of injury or role changes. Youth Sports and Escalating Pressure With increasing financial and performance stakes at younger ages, adolescent athletes face heightened mental health risk before full neurodevelopment. Neuromodulation in Addiction Emerging treatments—including transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), and vagus nerve stimulation (VNS)—target brain circuits involved in executive function and craving, particularly the prefrontal cortex. Executive Function and Craving Addiction involves planning, coordination, and decision-making processes—not simply impulsivity. Targeting prefrontal control circuits may influence compulsive behaviors and substance-seeking. Collaborative Care Model Effective addiction and sports psychiatry care requires collaboration among psychiatrists, psychologists, social workers, trainers, coaches, and family members to identify behavioral changes early and provide coordinated support. Key Takeaway Addiction in the modern era extends beyond substances to include digital and behavioral reinforcers embedded in everyday life. A biopsychosocial framework—combined with integrated treatment, executive function support, and collaborative care—offers the most effective approach for addressing substance use disorders and behavioral addictions alike. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Justin Morales: Here

In this episode of MD Newsline, Dr. Amber Johnson, Assistant Professor of Medicine and General Cardiologist at the University of Chicago, provides an in-depth look at modern cholesterol management and cardiovascular risk reduction. She discusses evolving lipid guidelines, aggressive LDL-C targets, statin intolerance, and the growing role of non-statin therapies. Dr. Johnson also explores emerging research on lipoprotein(a), hypertriglyceridemia, and future directions in lipid-lowering treatment. Episode Highlights Evolving Cholesterol Management and ASCVD Risk Dr. Johnson explains how cholesterol treatment has become more aggressive over the past decade, driven by robust evidence linking LDL cholesterol to cardiovascular events. She emphasizes LDL-C as the primary treatment target and discusses the role of HDL, triglycerides, and inflammatory markers such as high-sensitivity CRP, particularly in women. Lifestyle Modification and Population-Level Prevention Heart-healthy lifestyle interventions remain foundational to cardiovascular prevention. Dr. Johnson highlights the American Heart Association's Life's Essential Eight, including physical activity, diet, sleep, and smoking cessation, as critical components of long-term risk reduction. Key Updates in 2025 Dyslipidemia Guidelines Dr. Johnson reviews the 2025 ESC/EAS-focused update, emphasizing lower LDL-C targets for high- and extreme-risk patients. She discusses the increasing use of PCSK9 inhibitors, adjunct lipid-lowering therapies, and the recommendation for routine lipoprotein(a) screening as a risk-modifying factor. Risk Assessment and Personalized Treatment Decisions For primary prevention patients, Dr. Johnson outlines how risk calculators, coronary artery calcium scoring, and comorbidities such as diabetes and metabolic syndrome guide lipid-lowering intensity. She also addresses how updated endocrine and diabetes guidelines influence earlier and more aggressive treatment strategies. Statin Intolerance and Treatment Sequencing Persistent barriers to statin use include side effect concerns, cost, and polypharmacy. Dr. Johnson shares practical strategies for managing statin intolerance, including dose adjustments, switching statins, alternate-day dosing, and the addition of non-statin therapies such as ezetimibe, bempedoic acid, and PCSK9 inhibitors. Non-Statin Therapies and New Treatment Options Dr. Johnson discusses when to escalate therapy to PCSK9 inhibitors, including monoclonal antibodies and siRNA-based agents like inclisiran. She also explains how cost, access, and insurance coverage influence real-world treatment decisions. Triglycerides and Emerging Lipid Targets While triglycerides are often overlooked, Dr. Johnson reviews their clinical significance, particularly in severe hypertriglyceridemia. She discusses lifestyle interventions, fibrates, omega-3 therapies, and emerging agents targeting ANGPTL3 and APOC-3. The Role of Lipoprotein(a) Routine Lp(a) screening is gaining momentum due to its strong association with cardiovascular disease and aortic stenosis. Dr. Johnson reviews current guideline recommendations, clinical utility, and ongoing outcome trials such as OCEAN and HORIZON that may soon reshape treatment options. Special Populations and Complex Care Dr. Johnson addresses lipid management in patients with chronic kidney disease, HIV, inflammatory diseases, and cancer, emphasizing individualized therapy and careful consideration of drug–drug interactions. Future Directions in Lipid Therapy Looking ahead, Dr. Johnson explores long-acting therapies and gene-editing approaches such as CRISPR, while highlighting the importance of health equity, access to care, and sustainable lifestyle interventions. Key Takeaway Dr. Johnson underscores that lower LDL cholesterol is better, with no identified lower limit of harm, and highlights the growing importance of lipoprotein(a) screening in cardiovascular risk assessment. As lipid therapies continue to evolve, combining guideline-driven care, patient-centered decision-making, and equitable access remains essential to improving long-term cardiovascular outcomes. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Amber Johnson: Here

In this episode of MD Newsline, Dr. Rudolph J. Castellani, a neuropathologist and Director of the Division of Neuropathology at Northwestern University, offers a deep dive into the biology, diagnosis, and ongoing controversies surrounding Alzheimer's disease. He explores how Alzheimer's is defined clinically and pathologically, the evolving role of biomarkers in early detection, and why modifying biomarkers has not yet translated into meaningful clinical improvement for patients. Dr. Castellani also discusses the promise and limitations of artificial intelligence, personalized medicine, and lifestyle interventions in Alzheimer's research and care. Episode Highlights Defining Alzheimer's Disease Dr. Castellani explains how Alzheimer's disease can be defined clinically—through progressive memory and cognitive decline—or pathologically, based on hallmark brain lesions such as amyloid plaques and neurofibrillary tangles identified post-mortem. These structural changes remain central to diagnosis but do not fully explain disease progression. The Role of Amyloid and Biomarkers Amyloid beta, a key component of senile plaques, can now be detected through cerebrospinal fluid testing, blood-based biomarkers, and PET imaging. Dr. Castellani discusses how biomarkers help identify disease presence earlier but raises important questions about whether amyloid is a driver of disease or merely an associated marker. Early Detection: Promise and Ethical Concerns While biomarkers allow detection before symptoms appear, Dr. Castellani highlights the ethical dilemma of diagnosing asymptomatic individuals. He questions whether early identification without effective intervention may increase anxiety without improving outcomes. Therapies and Clinical Trial Limitations New anti-amyloid therapies, including FDA-approved agents, show only marginal cognitive benefit in highly selected trial populations. Dr. Castellani emphasizes caution when extrapolating these results to broader, more diverse patient groups and underscores the potential risks and toxicities associated with these treatments. Artificial Intelligence and Predictive Modelling AI and machine learning may enhance predictive modeling by integrating biomarkers, genetics, and cognitive data. However, Dr. Castellani notes that prediction alone is insufficient without therapies that meaningfully alter disease progression. Age of Onset and Risk Factors Alzheimer's disease can present as early as a patient's 30s in rare genetic cases or later in life in sporadic forms. Dr. Castellani reviews known risk factors, including APOE genotype, hypertension, diabetes, hearing loss, and traumatic brain injury, while stressing that many associations remain poorly understood. Personalized Medicine and Genetic Counseling Genetic testing—particularly for APOE and pathogenic mutations—plays a role in personalized risk assessment. Dr. Castellani emphasizes the importance of careful counseling, as not all individuals want or benefit from knowing their genetic risk. Supportive and Interdisciplinary Care With no curative treatments available, interdisciplinary care involving neurologists, neuropsychologists, and social workers is essential. Dr. Castellani highlights the importance of caregiver support, expectation management, and access to specialized centers. Lifestyle and Prevention Although lifestyle changes may not alter the underlying biology of Alzheimer's disease, healthy diet, exercise, and reducing inflammation and oxidative stress can improve quality of life and overall health. Key Takeaway Dr. Castellani underscores that while biomarkers and amyloid-focused therapies dominate current Alzheimer's research, they have not yet delivered meaningful clinical improvement. A broader research approach—beyond amyloid—combined with realistic expectations, ethical care, and strong support systems is essential for patients and families navigating Alzheimer's disease. Resources MD Newsline Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Rudolph J. Castellani: Here

In this episode of MD Newsline, Dr. Quentin Youmans, a heart failure cardiologist at Northwestern Medicine, explores the rapidly evolving landscape of advanced heart failure care. He shares insights into guideline-directed medical therapy, emerging device-based interventions, and the growing role of personalized medicine in improving outcomes for patients with complex cardiovascular disease. Dr. Youmans also addresses health disparities, access challenges, and the importance of multidisciplinary collaboration in modern cardiology. Episode Highlights Advances in Guideline-Directed Medical Therapy (GDMT) Dr. Youmans discusses the four pillars of GDMT for heart failure with reduced ejection fraction and how rapid initiation and optimization of therapy can significantly improve patient outcomes. He emphasises early sequencing, close follow-up, and collaboration with pharmacy teams to ensure patients receive maximal benefit. Device-Based Therapies in Advanced Heart Failure Innovations such as transcatheter mitral valve repair, pulmonary artery pressure monitoring, and advanced hemodynamic devices are reshaping heart failure care. Dr. Youmans explains how these technologies help reduce hospitalizations, improve symptoms, and support earlier intervention in high-risk patients. Health Disparities and Access to Care A major focus of the conversation centers on racial, socioeconomic, and geographic disparities in heart failure outcomes. Dr. Youmans highlights efforts to expand access through community-based clinics, telehealth, and outreach to rural and underserved populations. Sex-Based Differences and Cardiovascular Risk Across the Lifespan Dr. Youmans explores how pregnancy-related conditions such as preeclampsia increase long-term cardiovascular risk for women. He underscores the need for coordinated care between cardiology, OB-GYN, and primary care to support prevention and long-term monitoring. Multidisciplinary and Collaborative Care Models Heart failure management increasingly relies on collaboration across specialties, including nephrology, endocrinology, interventional cardiology, and surgery. Dr. Youmans discusses how integrated care models improve decision-making and patient outcomes, particularly in complex cases involving CKM (cardiovascular-kidney-metabolic) syndrome. Personalized Medicine and Biomarkers Biomarkers such as BNP play a growing role in risk stratification and treatment monitoring. Dr. Youmans explains how future approaches may tailor therapies based not only on biology, but also on patients' social environments and barriers to care. Emerging Therapies and the Future of Heart Failure Treatment From SGLT2 inhibitors and GLP-1 receptor agonists to new mineralocorticoid receptor antagonists, Dr. Youmans reviews promising pharmacologic advances for both HFrEF and HFpEF. He also shares perspectives on future innovations, including fully implantable LVADs, organ preservation technologies, and transplant expansion strategies. Key Takeaway Dr. Youmans emphasizes that the future of heart failure care lies at the intersection of innovation, equity, and collaboration. By combining advanced therapies with patient-centered communication and improved access, clinicians can meaningfully transform outcomes for diverse patient populations. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Quentin Youmans: Here

In this episode of MD Newsline, Dr. Joel Wright, a rheumatology fellow at UCLA, provides an in-depth, practical discussion on axial spondyloarthritis and related spondyloarthritides. Dr. Wright breaks down evolving disease definitions, diagnostic challenges, imaging interpretation, and modern treatment strategies, while emphasizing a holistic, patient-centered approach to care. The conversation highlights how early recognition and individualized therapy can significantly improve long-term outcomes. Episode Highlights Defining Axial vs. Peripheral Spondyloarthritis Dr. Wright explains the modern classification of spondyloarthritis, distinguishing axial disease—which primarily affects the spine and sacroiliac joints—from peripheral spondyloarthritis and psoriatic arthritis. He discusses why the shift away from the term ankylosing spondylitis allows for earlier diagnosis before irreversible spinal fusion occurs. Recognizing Red Flags Across Specialties Inflammatory back pain remains the most important clinical clue, particularly pain that worsens at rest, improves with exercise, and is associated with prolonged morning stiffness. Dr. Wright also highlights extra-musculoskeletal signs—such as uveitis, psoriasis, and inflammatory bowel disease—that should prompt early referral to rheumatology. Classification Criteria vs. Clinical Judgment While ASAS classification criteria are useful for research, Dr. Wright emphasizes that real-world diagnosis relies on clinical expertise. Patients may not meet strict criteria early in the disease course, yet still warrant diagnosis and treatment based on symptoms, exam findings, labs, and imaging. MRI Use and Common Diagnostic Pitfalls MRI of the sacroiliac joints plays a central role in early detection, but Dr. Wright cautions against overreliance on imaging alone. Bone marrow edema can be seen in athletes, postpartum patients, or with aging, underscoring the importance of correlating MRI findings with clinical context. Biomarkers and Emerging Research HLA-B27, ESR, and CRP remain useful tools, though many patients have normal inflammatory markers. Dr. Wright discusses emerging biomarkers, including antibodies such as anti-CD74, and the need for more reliable tools to support earlier diagnosis. Treatment Algorithms and Medication Selection NSAIDs remain first-line therapy and may slow radiographic progression. For patients with inadequate response, Dr. Wright outlines escalation to biologics, including TNF inhibitors, IL-17 inhibitors, and JAK inhibitors—while tailoring choices based on comorbidities such as uveitis or inflammatory bowel disease. Treat-to-Target and Monitoring Early disease requires more frequent follow-up to assess response and adjust therapy. Dr. Wright explains realistic timelines for evaluating NSAIDs and biologics while balancing treat-to-target goals with clinic capacity. The Role of Exercise and Non-Pharmacologic Care Physical therapy, structured exercise, and low-impact activities such as swimming and cycling are foundational to care. Dr. Wright emphasizes the mental and physical benefits of movement, posture training, and holistic therapies alongside medication. Managing Comorbidities and Special Populations The discussion covers cardiovascular risk screening, adherence challenges in younger patients, biologic tapering in remission, pregnancy considerations, and care for older adults with established structural damage. Shared decision-making remains central across all scenarios. Key Takeaway Dr. Wright underscores that axial spondyloarthritis requires early recognition, thoughtful interpretation of imaging, and individualized treatment strategies. Combining pharmacologic therapy with exercise, multidisciplinary care, and patient education is essential to improving quality of life and preventing long-term disability. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Joel Wright: Here